Long-term exposure to hexavalent chromium inhibits expression of tumor suppressor genes in cultured cells and in mice

Journal of Trace Elements in Medicine and Biology

Volumn 26, Issue 2-3, 2012, Pages 188-191

  Fan, Yunxia ^a   Ovesen, Jerald L ^a   Puga, Alvaro ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Benzo a pyrene; Complex mixtures; Epigenetics; Gene expression; Hexavalent chromium

Indexed keywords

BENZO[A]PYRENE; CHROMIUM; CYTOCHROME P450 1B1; DRINKING WATER; HEXAVALENT CHROMIUM; MESSENGER RNA; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P19; PROTEIN P21; PROTEIN P27; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CHROMATIN; CONCENTRATION RESPONSE; CYP1B1 GENE; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE EXPRESSION REGULATION; HEPATOMA CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; MOUSE; NONHUMAN; P15 GENE; P16 GENE; P18 GENE; P19 GENE; P21 GENE; P27 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; BENZOPYRENES; CELLS, CULTURED; CHROMIUM; EPIGENESIS, GENETIC; GENE EXPRESSION; MICE; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84862584079     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2012.04.009     Document Type: Article

References (33)

1. Sexton K., Beck B.D., Bingham E., Brain J.D., DeMarini D.M., Hertzberg R.C., et al. Chemical mixtures from a public health perspective: the importance of research for informed decision making. Toxicology 1995, 105:429-441.
2. Birnbaum L.S., DeVito M.J. Use of toxic equivalency factors for risk assessment for dioxins and related compounds. Toxicology 1995, 105:391-401.
3. Collins J.F., Brown J.P., Alexeeff G.V., Salmon A.G. Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Regul Toxicol Pharmacol 1998, 28:45-54.
4. Cizmas L., McDonald T.J., Phillips T.D., Gillespie A.M., Lingenfelter R.A., Kubena L.F., et al. Toxicity characterization of complex mixtures using biological and chemical analysis in preparation for assessment of mixture similarity. Environ Sci Technol 2004, 38:5127-5133.
5. IARC Evaluation of the carcinogenic risk to humans. Chromium, nickel and welding 1990, International Agency for Research on Cancer, Lyon, France.
6. Hamilton J.W., Wetterhahn K.E. Differential effects of chromium(VI) on constitutive and inducible gene expression in chick embryo liver in vivo and correlation with chromium(VI)-induced DNA damage. Mol Carcinog 1989, 2:274-286.
7. Salnikow K., Zhitkovich A., Costa M. Analysis of the binding sites of chromium to DNA and protein in vitro and in intact cells. Carcinogenesis 1992, 13:2341-2346.
8. Xu J., Manning F.C., Patierno S.R. Preferential formation and repair of chromium-induced DNA adducts and DNA-protein crosslinks in nuclear matrix DNA. Carcinogenesis 1994, 15:1443-1450.
9. Quievryn G., Messer J., Zhitkovich A. Lower mutagenicity but higher stability of Cr-DNA adducts formed during gradual chromate activation with ascorbate. Carcinogenesis 2006, 27:2316-2321.
10. Reynolds M., Stoddard L., Bespalov I., Zhitkovich A. Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair. Nucleic Acids Res 2007, 35:465-476.
11. Salnikow K., Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol 2008, 21:28-44.
12. Ha L., Ceryak S., Patierno S.R. Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein. Requirement of ATM for both apoptosis and recovery from terminal growth arrest. J Biol Chem 2003, 278:17885-17894.
13. Ha L., Ceryak S., Patierno S.R. Generation of S phase-dependent DNA double-strand breaks by Cr(VI) exposure: involvement of ATM in Cr(VI) induction of gamma-H2AX. Carcinogenesis 2004, 25:2265-2274.
14. Xu J., Manning F.C., O'Brien T.J., Ceryak S., Patierno S.R. Mechanisms of chromium-induced suppression of RNA synthesis in cellular and cell-free systems: relationship to RNA polymerase arrest. Mol Cell Biochem 2004, 255:151-160.
15. Wakeman T.P., Kim W.J., Callens S., Chiu A., Brown K.D., Xu B. The ATM-SMC1 pathway is essential for activation of the chromium[VI]-induced S-phase checkpoint. Mutat Res 2004, 554:241-251.
16. Shumilla J.A., Broderick R.J., Wang Y., Barchowsky A. Chromium(VI) inhibits the transcriptional activity of nuclear factor-kappaB by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein. J Biol Chem 1999, 274:36207-36212.
17. O'Hara K.A., Nemec A.A., Alam J., Klei L.R., Mossman B.T., Barchowsky A. Chromium (VI) inhibits heme oxygenase-1 expression in vivo and in arsenic-exposed human airway epithelial cells. J Cell Physiol 2006, 209:113-121.
18. Schnekenburger M., Talaska G., Puga A. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. Mol Cell Biol 2007, 27:7089-7101.
19. Chen L., Ovesen J.L., Puga A., Xia Y. Distinct contributions of JNK and p38 to chromium cytotoxicity and inhibition of murine embryonic stem cell differentiation. Environ Health Perspect 2009, 117:1124-1130.
20. Klein C.B. Carcinogenicity and genotoxicity of chromium. Toxicology of metals 1996, 205-219. CRC Press Inc., Boca Raton, FL. L.W. Chang (Ed.).
21. Alcedo J.A., Misra M., Hamilton J.W., Wetterhahn K.E. The genotoxic carcinogen chromium(VI) alters the metal-inducible expression but not the basal expression of the metallothionein gene in vivo. Carcinogenesis 1994, 15:1089-1092.
22. McCaffrey J., Wolf C.M., Hamilton J.W. Effects of the genotoxic carcinogen chromium(VI) on basal and hormone-inducible phosphoenolpyruvate carboxykinase gene expression in vivo: correlation with glucocorticoid- and developmentally regulated expression. Mol Carcinog 1994, 10:189-198.
23. Maier A., Schumann B.L., Chang X., Talaska G., Puga A. Arsenic co-exposure potentiates benzo[a]pyrene genotoxicity. Mutat Res 2002, 517:101-111.
24. Manning F.C., Xu J., Patierno S.R. Transcriptional inhibition by carcinogenic chromate: relationship to DNA damage. Mol Carcinog 1992, 6:270-279.
25. Kim G., Yurkow E.J. Chromium induces a persistent activation of mitogen-activated protein kinases by a redox-sensitive mechanism in H4 rat hepatoma cells. Cancer Res 1996, 56:2045-2051.
26. Chen F., Ye J., Zhang X., Rojanasakul Y., Shi X. One-electron reduction of chromium(VI) by alpha-lipoic acid and related hydroxyl radical generation, dG hydroxylation and nuclear transcription factor-kappaB activation. Arch Biochem Biophys 1997, 338:165-172.
27. Ye J., Zhang X., Young H.A., Mao Y., Shi X. Chromium(VI)-induced nuclear factor-kappa B activation in intact cells via free radical reactions. Carcinogenesis 1995, 16:2401-2405.
28. Nebert D.W., Puga A., Vasiliou V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann N Y Acad Sci 1993, 685:624-640.
29. Tesfai Y., Davis D., Reinhold D. Chromium can reduce the mutagenic effects of benzo[a]pyrene diolepoxide in normal human fibroblasts via an oxidative stress mechanism. Mutat Res 1998, 416:159-168.
30. Feng Z., Hu W., Rom W.N., Costa M., Tang M.S. Chromium(VI) exposure enhances polycyclic aromatic hydrocarbon-DNA binding at the p53 gene in human lung cells. Carcinogenesis 2003, 24:771-778.
31. Jarmalaite S., Kannio A., Anttila S., Lazutka J.R., Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003, 106:913-918.
32. Kim D.H., Nelson H.H., Wiencke J.K., Zheng S., Christiani D.C., Wain J.C., et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001, 61:3419-3424.
33. Kondo K., Takahashi Y., Hirose Y., Nagao T., Tsuyuguchi M., Hashimoto M., et al. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. Lung Cancer 2006, 53:295-302.